Yilie Liao’s dedication to addressing vital biological questions in metabolic health and his breadth of expertise in both technical and conceptual aspects of biology position him as an exceptional candidate for the Research for Best Researcher Award. His innovative findings, technical versatility, and contributions to high-impact publications underscore his potential for continued advancements in biology.
Education
Yilie Liao obtained her Ph.D. in Biology from the School of Life Sciences at Tsinghua University in 2020, where she conducted groundbreaking research under the mentorship of Dr. Suneng Fu. Her doctoral studies focused on metabolic reprogramming in metabolic diseases and neural development. Previously, she earned her B.Sc. in Biological Science from Nanjing Agricultural University in 2013. Her undergraduate education laid the foundation for her interest in integrative biology and metabolic research. Throughout her academic journey, Yilie acquired a robust skill set, encompassing molecular biology techniques, data analysis, and metabolomic profiling. Her proficiency in multi-omics data analysis, combined with a strong foundation in biological sciences, has enabled her to explore complex biochemical pathways and cellular processes. Her educational background reflects her commitment to advancing scientific knowledge and tackling complex issues in metabolic diseases and cellular biology.
Experience
Yilie Liao’s research career spans several prestigious institutions and roles, each contributing to her expertise in metabolic biology. She is currently an Assistant Research Scientist at Zhongshan Institute for Drug Discovery under the Shanghai Institute of Materia Medica. From 2021 to 2023, she worked as a Postdoctoral Fellow at Bioland Laboratories, investigating neurodevelopmental and metabolic disease mechanisms under Prof. Peng Li. In 2022, she was a visiting researcher at Duke-NUS Medical School, exploring novel metabolic pathways with renowned scientists Prof. Weiping Han and Dr. Alfred Sun. Her projects have included identifying SLC transporters in the central nervous system and studying metabolic substrates impacting liver and brain health. Through these roles, Yilie has acquired extensive experience in experimental design, data mining, and integrative biology, making her a leading expert in her field with substantial contributions to metabolic disease research.
Awards and Honors
Yilie Liao’s contributions to metabolic biology and her dedication to advancing scientific understanding have earned her numerous accolades. Her work on hepatic lipogenesis and metabolic reprogramming has been recognized with prestigious awards from leading scientific societies, highlighting her impact in biomedical research. She has received notable recognition from the Chinese Academy of Sciences for her innovative work in translational research and metabolic disease. As a testament to her expertise, she has been a recipient of research grants supporting her studies on cellular metabolism, neurodevelopment, and tumorigenesis. Yilie’s publications in high-impact journals such as Cell Metabolism and Hepatology further underscore her prominence in the field. Her academic and professional honors reflect her commitment to scientific excellence and her potential to drive significant advancements in biological and metabolic research.
Research Focus
Yilie Liao’s research centers on uncovering the intricate mechanisms of metabolic reprogramming in health and disease. She investigates how metabolic pathways influence conditions such as obesity, neurodevelopmental disorders, and cancer, with a particular focus on the role of amino acids in hepatic lipogenesis. Her recent work explores SLC transporters’ influence in the central nervous system and their impact on brain functions. Additionally, her research extends to the identification of metabolic markers in Alzheimer’s disease, using single-cell sequencing to reveal early dysfunctions. She is also involved in studying tumor microenvironment metabolic changes, with implications for early diagnosis and treatment of liver cancer. Through her work, Yilie aims to provide insight into metabolic diseases and develop novel therapeutic approaches that address metabolic imbalances, contributing to the broader field of translational medicine.
Publication Top Notes
-
Amino acid is a major carbon source for hepatic lipogenesis
-
Hepatic mitochondrial NAD+ transporter SLC25A47 activates AMPKα mediating lipid metabolism and tumorigenesis
-
Genetic Ablation of LAT1 Inhibits Growth of Liver Cancer Cells and Downregulates mTORC1 Signaling